133 related articles for article (PubMed ID: 36099787)
1. The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity - A systematic review and meta-analysis.
Mahdi Seyedzadeh Sani S; Sahranavard M; Jannati Yazdanabad M; Seddigh Shamsi M; Elyasi S; Hooshang Mohammadpour A; Sathyapalan T; Arasteh O; Ghavami V; Sahebkar A
Int Immunopharmacol; 2022 Nov; 112():109227. PubMed ID: 36099787
[TBL] [Abstract][Full Text] [Related]
2. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor
Andersen MD; Kamper P; d'Amore A; Clausen M; Bentzen H; d'Amore F
Leuk Lymphoma; 2019 Apr; 60(4):927-933. PubMed ID: 30277120
[TBL] [Abstract][Full Text] [Related]
3. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
5. Bleomycin induced pulmonary toxicity in patients with germ cell tumours.
Usman M; Faruqui ZS; ud Din N; Zahid KF
J Ayub Med Coll Abbottabad; 2010; 22(3):35-7. PubMed ID: 22338413
[TBL] [Abstract][Full Text] [Related]
6. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Sun HL; Atenafu EG; Tsang R; Kukreti V; Marras TK; Crump M; Kuruvilla J
Leuk Lymphoma; 2017 Nov; 58(11):2607-2614. PubMed ID: 28504035
[TBL] [Abstract][Full Text] [Related]
8. Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.
Thomas TS; Luo S; Reagan PM; Keller JW; Sanfilippo KM; Carson KR
J Geriatr Oncol; 2020 Jan; 11(1):69-74. PubMed ID: 31668826
[TBL] [Abstract][Full Text] [Related]
9. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
Al-Jizani WA; Al-Mansour MM; Al-Fayea TM; Shafi RU; Kazkaz GA; Bayer AM; Al-Foheidi ME; Ibrahim EM
Future Oncol; 2015; 11(15):2149-57. PubMed ID: 26235180
[TBL] [Abstract][Full Text] [Related]
10. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
Ahmed BM; Al-Zakwani IS
J Oncol Pharm Pract; 2013 Mar; 19(1):3-7. PubMed ID: 22504168
[TBL] [Abstract][Full Text] [Related]
11. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.
O'Sullivan JM; Huddart RA; Norman AR; Nicholls J; Dearnaley DP; Horwich A
Ann Oncol; 2003 Jan; 14(1):91-6. PubMed ID: 12488299
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
Saxman SB; Nichols CR; Einhorn LH
Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary toxicity of bleomycin: is G-CSF a risk factor?
Bastion Y; Coiffier B
Lancet; 1994 Aug; 344(8920):474. PubMed ID: 7520108
[No Abstract] [Full Text] [Related]
14. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?
Abou Yehia Z; Mikhaeel GN; Smith G; Pinnix CC; Milgrom SA; Tang C; Jiang W; Fanale MA; Oki Y; Shank JH; Horace T; Reddy J; Akhtari M; Gunther JR; Suki T; Allen PK; Turner S; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):951-958. PubMed ID: 27742539
[TBL] [Abstract][Full Text] [Related]
15. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies.
Necchi A; Miceli R; Oualla K; Sonpavde G; Giannatempo P; Raggi D; Nicolai N; Boffi R; Busia A; Mariani L; Salvioni R
Clin Genitourin Cancer; 2017 Apr; 15(2):213-220.e5. PubMed ID: 27692810
[TBL] [Abstract][Full Text] [Related]
16. Risk of pulmonary toxicity of bleomycin and filgrastim.
Laprise-Lachance M; Lemieux P; Grégoire JP
J Oncol Pharm Pract; 2019 Oct; 25(7):1638-1644. PubMed ID: 30319063
[TBL] [Abstract][Full Text] [Related]
17. Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor.
McAvoy C; Fields P; Otto D; Kreimer A; Ellis CS
J Oncol Pharm Pract; 2024 Jan; ():10781552231225766. PubMed ID: 38291671
[TBL] [Abstract][Full Text] [Related]
18. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
Azoulay E; Herigault S; Levame M; Brochard L; Schlemmer B; Harf A; Delclaux C
Crit Care Med; 2003 May; 31(5):1442-8. PubMed ID: 12771616
[TBL] [Abstract][Full Text] [Related]
19. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
Taparra K; Liu H; Polley MY; Ristow K; Habermann TM; Ansell SM
Leuk Lymphoma; 2020 Feb; 61(2):298-308. PubMed ID: 31517559
[TBL] [Abstract][Full Text] [Related]
20. The role of screening and monitoring for bleomycin pulmonary toxicity.
Shippee BM; Bates JS; Richards KL
J Oncol Pharm Pract; 2016 Apr; 22(2):308-12. PubMed ID: 25736276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
